Literature DB >> 7514854

Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions.

R F Schinazi1, R M Lloyd, C S Ramanathan, E W Taylor.   

Abstract

A statistically significant correlation exists between the locations of drug resistance mutations (DRMs) observed for various reverse transcriptase inhibitors and features of the secondary structure predicted for the RNA coding for human immunodeficiency virus type 1 reverse transcriptase. The known DRMs map onto "unstable" bases, which are predominantly nonhelical regions (i.e., loops, bulges, and bends) of the predicted RNA secondary structure, whereas codons for the key conserved residues of polymerase sequence motifs map onto "stable" paired bases involved in helical regions. On the basis of these results, we hypothesize that the secondary structure of the RNA template (in this case, the reverse transcriptase gene itself) may be a previously unrecognized factor contributing to base misincorporation errors during reverse transcription and that, rather than being randomly distributed, mutations are more likely to occur in specific regions of the genome. The results suggest that these "mutation-prone" regions can be predicted by using a standard algorithm for RNA secondary structure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514854      PMCID: PMC284439          DOI: 10.1128/AAC.38.2.268

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.

Authors:  J Balzarini; A Karlsson; M J Pérez-Pérez; L Vrang; J Walbers; H Zhang; B Oberg; A M Vandamme; M J Camarasa; E De Clercq
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

2.  Protein structure and introns.

Authors:  G Wistow
Journal:  Nature       Date:  1993-07-08       Impact factor: 49.962

3.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

4.  Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information.

Authors:  M Zuker; P Stiegler
Journal:  Nucleic Acids Res       Date:  1981-01-10       Impact factor: 16.971

5.  Computer support of DNA sequence analysis.

Authors:  G Osterburg; R Sommer
Journal:  Comput Programs Biomed       Date:  1981 Mar-Jun

6.  Energy directed folding of RNA sequences.

Authors:  P Hogeweg; B Hesper
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

7.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

8.  Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors.

Authors:  V W Byrnes; V V Sardana; W A Schleif; J H Condra; J A Waterbury; J A Wolfgang; W J Long; C L Schneider; A J Schlabach; B S Wolanski
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

9.  The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.

Authors:  Q Gao; Z Gu; M A Parniak; J Cameron; N Cammack; C Boucher; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  Sequence divergence and open regions of RNA secondary structures in the envelope regions of the 17 human immunodeficiency virus isolates.

Authors:  S Y Le; J H Chen; D Chatterjee; J V Maizel
Journal:  Nucleic Acids Res       Date:  1989-04-25       Impact factor: 16.971

View more
  8 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.

Authors:  G J Moyle
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

3.  Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.

Authors:  M Zazzi; M Catucci; A De Milito; L Romano; G Venturi; P Almi; A Gonnelli; M Rubino; P E Valensin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

4.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

Authors:  Bluma G Brenner; Dimitrios Coutsinos
Journal:  HIV Ther       Date:  2009-11-01

5.  Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine.

Authors:  Adrian S Ray; Brenda I Hernandez-Santiago; Judy S Mathew; Eisuke Murakami; Carey Bozeman; Meng-Yu Xie; Ginger E Dutschman; Elizabeth Gullen; Zhenjun Yang; Selwyn Hurwitz; Yung-Chi Cheng; Chung K Chu; Harold McClure; Raymond F Schinazi; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

6.  Evidence of a novel RNA secondary structure in the coding region of HIV-1 pol gene.

Authors:  Qi Wang; Ian Barr; Feng Guo; Christopher Lee
Journal:  RNA       Date:  2008-10-30       Impact factor: 4.942

7.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.

Authors:  I Nájera; A Holguín; M E Quiñones-Mateu; M A Muñoz-Fernández; R Nájera; C López-Galíndez; E Domingo
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

8.  A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1.

Authors:  Dimitrios Coutsinos; Cédric F Invernizzi; Daniela Moisi; Maureen Oliveira; Jorge L Martinez-Cajas; Bluma G Brenner; Mark A Wainberg
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.